Fatty liver disease (steatosis)

Main article: Liver

Fatty liver disease, also known as hepatic steatosis, occurs when fat accumulates in liver cells. The disease can occur when the liver contains more than five percent fat, according to a study published in the World Journal of Gastroenterology in 2017. This condition can be divided into alcoholic fatty liver disease (AHBP) and non-alcoholic fatty liver disease (NAFLD).

Alcoholic fatty liver disease is caused by excessive alcohol consumption, while NAFLD is associated with factors such as obesity, insulin resistance and metabolic syndrome, said gastroenterology, hepatology and liver transplantation expert Dr. Sukrit Singh Sethi. Fatty liver disease can manifest with various symptoms on the skin.

2022: Metabolic fatty liver disease detected in a third of the world's population

At the end of August 2022, scientists from the National University of Singapore and the University of Adelaide in Australia published data on the prevalence of metabolically associated fatty liver disease. According to experts, a third of the world's population has such a problem.

The researchers collected clinical data from 399 treatment-naïve chronic hepatitis (HH) patients who underwent liver biopsies. All patients were divided into two groups (HBeAg±gruppa). Logistic regression analysis was used to identify factors associated with hepatic inflammatory activity and significant fibrosis in patients with HG. Multivariable logistic regressions were repeated in subgroups stratified by HBeAg status. The analysis confirmed a relationship between metabolically associated fatty liver disease (MAJBP), diabetes, and hypertension.

Metabolic fatty liver disease detected in a third of the world's population

In patients with CH and MIBD was independently associated with a risk of moderate to severe liver activity and significant fibrosis (P <0,05). В HBeAg-отрицательной группе пациенты с МАФЛД имели значительно более высокие уровни аланиновой аминотрансферазы (АЛТ) (P <0,05) и более тяжелую воспалительную активность печени и фиброз (P <0,05) по сравнению с пациентами без МАЖБП. МАЖБП была независимо связана с риском умеренной или тяжелой активности печени (A ≥3: ОР 3,97, 95% ДИ 1,71-9,22, P =0,001) и значительного фиброза (F ≥2: ОР 2,02, 95% ДИ 1,09-3,73, P =0,026). В HBeAg-положительной группе МАЖБП была независимо связана с умеренной или тяжелой активностью печени (ОР 2,44, 95% ДИ 1,03-5,79, P =0,044), но не с фиброзом (P =0,618).

According to the August 2022 analysis, the global overall prevalence of metabolically associated fatty liver disease is 38.77%. At the same time, the disease occurs in 5.37% of thin people and in 29.78% of people without obesity.

The study suggests that the proposed term 'metabolically associated fatty liver disease' instead of 'non-alcoholic fatty liver disease' better reflects disease-related metabolic dysregulation. However, the introduction of the new definition calls into question the correctness of ideas about the disease.^[1]

2017: Rosacea link identified

The link between rosacea and fatty liver disease was discovered in a 2017 study published in the Journal of the American Academy of Dermatology.

Notes